Day One: Tuesday March 6, 2018

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Novel Antibody Constructs for Breast Cancer

8:30

(Title TBD) Antibody -Drug Conjugates for treatment of Triple Negative Breast Cancer

Aditya Bardia
Attending Physician

 

Massachusetts General Hospital Cancer Center

9:00

Development of Next Generation Calicheamicin-Based Antibody-Drug Conjugates



Omar Ahmad
Principal Scientist, Group Leader

 

Pfizer

9:30

10:00

Mechanistic Modeling of Antibody-Drug Conjugate Internalization

Kenneth Durbin
Senior Scientist II

 

AbbVie

Challenges in ADC Manufacturing: From Conjugation to Fill-Finish

 

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:30

Clinical Advances of Glembatumumab vedotin, a gpNMB ADC, in TNBC. Glembatumumab vedotin (GV) is a novel MMAE containing ADC that is being developed in breast cancer and other gpNMB expressing solid tumors

Christopher Turner

VP Clinical Science

 

Celldex Therapeutics

12:00

ZW25 – Preclinical and Clinical Development of a Novel Bispecific Antibody in HER2-Expressing Cancers

 

Nina Weisser

Principal Scientist

Zymeworks

LUNCH & NETWORKING

12:30

Immunotherapies in Breast Cancer

1:30

PD-1 inhibition for breast cancer treatment

 

 

Vassiliki Karantza

Senior Director, Clinical Research Oncology

 

Merck

2:00

Development of combination immunotherapy for breast cancer

 

 

Carol O'Hear

Associate Medical Director, Breast Cancer Immunotherapy Combination Group

 

Genentech

2:30

Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology

Mark Paris

Associate Director, Translational Applications

 

Mitra Biotech

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

Approaching breast cancer therapy with an intravenous reovirus: the scientific rationale

 

Andres Gutierrez

CMO

Oncolytics

4:00

Bria-IMT™/OTS™: An Off-The-Shelf Personalized Approach to Cancer Immunotherapy

 

William Williams

Chief Executive Officer

Briacell

4:30

Round table Discussions

Preclinical, Translational, Clinical development, Commercial

SUMMARY & CLOSE OF DAY ONE

5:30

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2016 | All content produced by: neo-synth ltd.

Registration

Aditya Bardia, MGH

Omar Ahmad, Pfizer

Kenneth Durbin, Abbvie

Conjugation & Fill/Finish at the Same Site, an Innovative Approach to the Supply of ADCs

 

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

Speed Networking

gpNMB: an important target for the ADC Glembatumumab vedotin in TNBC

 

 

Christopher Turner

VP Clinical Science

Celldex Therapeutics

Nina Weisser. Zymeworks

Lunch

Immunotherapy

PD-1 inhibition for breast cancer treatment

 

 

Vassiliki Karantza

Senior Director, Clinical Research Oncology

 

Merck

Carol O'Hear

Associate Medical Director, Breast Cancer Immunotherapy Combination Group

 

Genentech

Mark Paris, Mitra Biotech

Coffee Break

Andre Gutierrez,

Oncolytics

William Williams,

Briacell

End of Day 1

DOWNLOAD GUIDE